Comparison of entecavir and adefovir for the treatment of chronic hepatitis B.

肝胆速递

Braz J Infect Dis. 2012 Jul;16(4):366-72.
Comparison of entecavir and adefovir for the treatment of chronic hepatitis B.
Zhao SH, Liu EQ, Cheng DX, Li YF, Wang YL, Chen YL, Sun WT, Yan XC, Dang SS.
Source

Laboratory for Lipid Metabolism and Atherosclerosis, Xi'an Jiaotong University Cardiovascular Research Center, Shaanxi, China; Laboratory Animal Center, Xi'an Jiaotong University School of Medicine, Shaanxi, China.
Abstract

The results of several new clinical trials that compared the effectiveness of entecavir (ETV) treatment with that of adefovir (ADV) treatment in patients with chronic hepatitis B (CHB) were published in recent years. However, the numbers of patients included in these clinical trials were too small to draw a clear conclusion as to whether ETV is more effective than ADV. Therefore, a new meta-analysis was needed to compare ETV with ADV for the treatment of CHB. A search of the Cochrane Central Register of Controlled Trials (CCTR), MEDLINE, the Science Citation Index, Embase, the China National Knowledge Infrastructure (CNKI), and the Wanfang Database for relevant studies published between 1966 and 2010 was performed. Trials comparing the use of ETV and ADV for the treatment of CHB were assessed. Of the 2,358 studies screened, 13 randomized controlled clinical trials comprising 1,230 patients (ETV therapy, 621; ADV therapy, 609) were analyzed. The serum hepatitis B virus (HBV) DNA clearance rate obtained in patients treated with ETV was significantly higher than that in patients treated with ADV at the 24th and 48th weeks of treatment (24 weeks: 59.6% vs. 31.8%, relative risk [RR], 1.82, 95% CI: 1.49-2.23; 48 weeks: 78.3% vs. 50.4%, RR, 1.61, 95% CI: 1.32-1.96). The serum HBeAg clearance rate, the HBeAg seroconversion rate, and the ALT normalization rate obtained for patients treated with ETV were also higher than the corresponding values for patients treated with ADV at the 48th week of treatment. The safety profiles were similar between patients treated with ETV and those treated with ADV. The evidence reviewed in this meta-analysis suggests that patients with hepatitis B have a greater likelihood of achieving a viral response and a biomedical response when treated with ETV than when treated with ADV.

肝胆速递

布拉斯感染。 2012 07 16（4）:366-72。
恩替卡韦和阿德福韦酯用于治疗慢性乙型肝炎的比较
赵SH，陈，王，李YF刘EQ，程DX YL YL，严灿，孙WT，当SS。
源

脂质代谢和动脉粥样硬化，陕西，西安交通大学心血管研究中心，中国实验动物中心，西安交通大学医学院，陕西，中国的实验室。
抽象

发表在最近几年一些新的临床试验中，恩替卡韦（ETV），阿德福韦酯（ADV）治疗慢性乙型肝炎（CHB）患者的治疗效果比较的结果。然而，在这些临床试验的病人数目太小，无法得出一个明确的结论是否比ADV，ETV是更有效的。因此，一项新的荟萃分析，需要，比较ETV与ADV治疗慢性乙型肝炎。搜索Cochrane中心临床对照试验资料库（CCTR），MEDLINE，科学引文索引，文摘，中国国家知识基础设施工程（CNKI）和万方数据库，相关研究发表在1966年和2010年之间进行。试验比较ETV和ADV治疗慢性乙型肝炎的使用进行了评估。 2,358研究，筛选出13项随机对照临床试验，包括1230例患者（ETV治疗，621 ADV治疗，609）进行了分析。血清乙肝病毒（HBV）DNA清除率在恩替卡韦治疗的患者获得显着高于与ADV治疗的患者在第24周和第48周的治疗（24周：59.6％和31.8％，相对风险[RR ，1.82，95％CI：1.49-2.23 48周：78.3％比50.4％，RR，1.61，95％CI：1.32-1.96）。血清HBeAg清除率，HBeAg血清转换率，ALT复常率获得恩替卡韦治疗的患者也高于相应的值与ADV治疗的患者在48周的治疗。安全性之间与ETV并与ADV治疗的患者类似。检讨这项荟萃分析的证据表明，乙肝患者有更大的可能性的实现病毒的反应和生物医学的反应比与ADV治疗时，恩替卡韦治疗时，

咬牙硬挺

恩替效果比阿德好是大家都知道的了，阿德效果比拉米都弱，但不容易耐药